title: Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies.
authors.affiliation: Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA.
authors.forename: D V
authors.initials: DV
authors.lastname: Quon
authors.affiliation: Zentrum für Gefaßmedizin/Hämophiliezentrum, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Klamroth
authors.affiliation: Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA.
authors.forename: R
authors.initials: R
authors.lastname: Kulkarni
authors.affiliation: Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Shapiro
authors.affiliation: Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, Australia.
authors.forename: R I
authors.initials: RI
authors.lastname: Baker
authors.affiliation: Center for Bleeding Disorders, Careggi University Hospital, Florence, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Castaman
authors.affiliation: Nationwide Children's Hospital, Columbus, OH, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Kerlin
authors.affiliation: Biogen, Cambridge, MA, USA.
authors.forename: E
authors.initials: E
authors.lastname: Tsao
authors.affiliation: Biogen, Cambridge, MA, USA.
authors.forename: G
authors.initials: G
authors.lastname: Allen
mesh_terms: D015444:Exercise / Q000502:physiology*; D005169:Factor VIII / Q000009:adverse effects*; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans
chemical_list: D005169:Factor VIII